{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:24:03Z","timestamp":1772249043286,"version":"3.50.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004756","name":"Emil Aaltosen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize serum biomarkers in mitochondrial CHCHD10-linked spinal muscular atrophy Jokela (SMAJ) type for disease monitoring and for the understanding of pathogenic mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We collected serum samples from a cohort of 49 patients with SMAJ, all carriers of the heterozygous c.197G&amp;gt;T p.G66V variant in\n                      <jats:italic>CHCHD10<\/jats:italic>\n                      . As controls, we used age- and sex-matched serum samples obtained from Helsinki Biobank. Creatine kinase and creatinine were measured by standard methods. Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) were measured with single molecule array (Simoa), fibroblast growth factor 21 (FGF-21), and growth differentiation factor 15 (GDF-15) with an enzyme-linked immunosorbent assay. For non-targeted plasma metabolite profiling, samples were analyzed with liquid chromatography high-resolution mass spectrometry. Disease severity was evaluated retrospectively by calculating a symptom-based score.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Axon degeneration marker, NfL, was unexpectedly not altered in the serum of patients with SMAJ, whereas astrocytic activation marker, GFAP, was slightly decreased. Creatine kinase was elevated in most patients, particularly men. We identified six metabolites that were significantly altered in serum of patients with SMAJ in comparison to controls: increased creatine and pyruvate, and decreased creatinine, taurine, N-acetyl-carnosine, and succinate. Creatine correlated with disease severity. Altered pyruvate and succinate indicated a metabolic response to mitochondrial dysfunction; however, lactate or mitochondrial myopathy markers FGF-21 or GDF-15 was not changed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Biomarkers of muscle mass and damage are altered in SMAJ serum, indicating a role for skeletal muscle in disease pathogenesis in addition to neurogenic damage. Despite the minimal mitochondrial pathology in skeletal muscle, signs of a metabolic shift can be detected.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2022.793937","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:08:19Z","timestamp":1645056499000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy"],"prefix":"10.3389","volume":"13","author":[{"given":"Julius","family":"J\u00e4rvilehto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Harjuhaahto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Palu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Auranen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jouni","family":"Kvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Koskivuori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko","family":"Lehtonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maija","family":"Saukkonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manu","family":"Jokela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil","family":"Ylikallio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henna","family":"Tyynismaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1212\/WNL.0b013e3182267b71","article-title":"Late-onset lower motor neuronopathy: a new autosomal dominant disorder","volume":"77","author":"Jokela","year":"2011","journal-title":"Neurology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ana.24319","article-title":"Late onset spinal motor neuronopathy is caused by mutation in CHCHD10","volume":"77","author":"Penttila","year":"2015","journal-title":"Ann Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0151376","DOI":"10.1371\/journal.pone.0151376","article-title":"Distinct muscle biopsy findings in genetically defined adult-onset motor neuron disorders","volume":"11","author":"Jokela","year":"2016","journal-title":"PLoS ONE."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/NXG.0000000000000003","article-title":"CHCHD10 variant p.(Gly66Val) causes axonal charcot-marie-tooth disease","volume":"1","author":"Auranen","year":"2015","journal-title":"Neurol Genet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1093\/brain\/awu138","article-title":"A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement","volume":"137","author":"Bannwarth","year":"2014","journal-title":"Brain."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1093\/brain\/awu227","article-title":"Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease","volume":"137","author":"M\u00fcller","year":"2014","journal-title":"Brain."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10048-014-0421-1","article-title":"Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a family with autosomal dominant mitochondrial myopathy","volume":"16","author":"Ajroud-Driss","year":"2015","journal-title":"Neurogenetics."},{"key":"B8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00401-019-01989-y","article-title":"ALS\/FTD mutant CHCHD10 mice reveal a tissue-specific toxic gain-of-function and mitochondrial stress response","volume":"138","author":"Anderson","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00401-019-01988-z","article-title":"Mitochondrial defect in muscle precedes neuromuscular junction degeneration and motor neuron death in CHCHD10(S59L\/+) mouse","volume":"138","author":"Genin","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"104940","DOI":"10.1016\/j.nbd.2020.104940","article-title":"ALS and Parkinson's disease genes CHCHD10 and CHCHD2 modify synaptic transcriptomes in human iPSC-derived motor neurons","volume":"141","author":"Harjuhaahto","year":"2020","journal-title":"Neurobiol Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.15252\/emmm.201505496","article-title":"CHCHD10 mutations promote loss of mitochondrial cristae junctions with impaired mitochondrial genome maintenance and inhibition of apoptosis","volume":"8","author":"Genin","year":"2016","journal-title":"EMBO Mol Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.nbd.2018.07.027","article-title":"Loss of MICOS complex integrity and mitochondrial damage, but not TDP-43 mitochondrial localisation, are likely associated with severity of CHCHD10-related diseases","volume":"119","author":"Genin","year":"2018","journal-title":"Neurobiol Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/hmg\/ddz154","article-title":"Loss of mitochondrial protein CHCHD10 in skeletal muscle causes neuromuscular junction impairment","volume":"29","author":"Xiao","year":"2020","journal-title":"Hum Mol Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/hmg\/ddab078","article-title":"Multi-OMICS study of a CHCHD10 variant causing ALS demonstrates metabolic rewiring and activation of endoplasmic reticulum and mitochondrial unfolded protein responses","volume":"30","author":"Straub","year":"2021","journal-title":"Hum Mol Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1529-8027.2011.00350.x","article-title":"Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease","volume":"16","author":"Murphy","year":"2011","journal-title":"J Peripher Nerv Syst."},{"key":"B16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3390\/metabo10040135","article-title":"\u201cnotame\u201d: workflow for non-targeted LC-MS metabolic profiling","volume":"10","author":"Kl\u00e5vus","year":"2020","journal-title":"Metabolites"},{"key":"B17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Lu","year":"2015","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/acn3.50965","article-title":"Transmembrane protease serine 5: a novel Schwann cell plasma marker for CMT1A","volume":"7","author":"Wang","year":"2020","journal-title":"Ann Clin Transl Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00415-019-09547-y","article-title":"Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen","volume":"267","author":"Wurster","year":"2020","journal-title":"J Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1440-1819.1998.tb02706.x","article-title":"A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer's disease, normal controls and non-Alzheimer neuropsychiatric diseases","volume":"52","author":"Muramori","year":"1998","journal-title":"Psychiatry Clin Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1474-4422(11)70155-7","article-title":"FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study","volume":"10","author":"Suomalainen","year":"2011","journal-title":"Lancet Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mito.2014.10.006","article-title":"GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases","volume":"20","author":"Fujita","year":"2015","journal-title":"Mitochondrion."},{"key":"B24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.nmd.2013.11.010","article-title":"Late-onset spinal motor neuronopathy-a common form of dominant SMA","volume":"24","author":"Penttil\u00e4","year":"2014","journal-title":"Neuromuscul Disord."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1212\/WNL.0000000000004029","article-title":"Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease","volume":"88","author":"Poesen","year":"2017","journal-title":"Neurology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B27","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00415-019-09389-8","article-title":"NFL is a marker of treatment response in children with SMA treated with nusinersen","volume":"266","author":"Olsson","year":"2019","journal-title":"J Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1756286419846058","DOI":"10.1177\/1756286419846058","article-title":"Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment","volume":"12","author":"Wurster","year":"2019","journal-title":"Ther Adv Neurol Disord."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1111\/jcmm.14939","article-title":"Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients","volume":"24","author":"Faravelli","year":"2020","journal-title":"J Cell Mol Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","article-title":"Plasma neurofilament light chain concentration in the inherited peripheral neuropathies","volume":"90","author":"Sandelius","year":"2018","journal-title":"Neurology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1205","DOI":"10.1212\/WNL.0000000000007097","article-title":"Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy","volume":"92","author":"Lombardi","year":"2019","journal-title":"Neurology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/acn3.324","article-title":"Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy","volume":"3","author":"Hijikata","year":"2016","journal-title":"Ann Clin Transl Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e921","DOI":"10.1212\/WNL.0000000000008762","article-title":"Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy","volume":"94","author":"Alves","year":"2020","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/acn3.51340","article-title":"Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment","volume":"8","author":"Freigang","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1373\/clinchem.2006.081166","article-title":"Diagnostic accuracy of blood lactate-to-pyruvate molar ratio in the differential diagnosis of congenital lactic acidosis","volume":"53","author":"Debray","year":"2007","journal-title":"Clin Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e9091","DOI":"10.15252\/emmm.201809091","article-title":"Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers","volume":"10","author":"Buzkova","year":"2018","journal-title":"EMBO Mol Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1073\/pnas.0906039107","article-title":"A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells","volume":"107","author":"Shaham","year":"2010","journal-title":"Proc Natl Acad Sci U S A."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.793937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:08:25Z","timestamp":1645056505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.793937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":38,"alternative-id":["10.3389\/fneur.2022.793937"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.793937","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.07.21254960","asserted-by":"object"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"article-number":"793937"}}